Clinical Trials Logo

Clinical Trial Details — Status: Completed

Administrative data

NCT number NCT06180213
Other study ID # FDG-PET
Secondary ID
Status Completed
Phase
First received
Last updated
Start date October 1, 2015
Est. completion date December 31, 2019

Study information

Verified date December 2023
Source IRCCS San Raffaele
Contact n/a
Is FDA regulated No
Health authority
Study type Observational

Clinical Trial Summary

The reason why each specific degenerative disease is characterized by a different FDG PET pattern is still unclear today. There are four main hypotheses proposed to explain this selective vulnerability: 1) Nodal stress, theory according to which the main nodes of specific brain networks undergo wear and tear, 2) trans-neuronal diffusion, theory according to which some toxic agents/proteins or altered propagate along network connections through "Prion-like" mechanisms, 3) trophic failure, in which the interruption of inter-modal connectivity causes the loss of collateral trophic factors, and finally 4) shared vulnerability in which regions also distant from each other are part of a common network which gives a susceptibility uniformly distributed throughout the network. FDG PET provides in-vivo information on the distribution of brain synaptic dysfunction prior to complete neural death, and represents the main in vivo biomarker of neural dysfunction associated with different clinical conditions characterized by neurodegeneration phenomena. For this reason, FDG PET is considered a fundamental approach to shed light on the causes of selective brain vulnerability in various pathological conditions.


Recruitment information / eligibility

Status Completed
Enrollment 1570
Est. completion date December 31, 2019
Est. primary completion date December 31, 2019
Accepts healthy volunteers
Gender All
Age group 18 Years and older
Eligibility Inclusion Criteria: - presence of diagnosis of neurodegenerative disease. Exclusion Criteria: - patients< 18 years

Study Design


Related Conditions & MeSH terms


Intervention

Diagnostic Test:
FDG PET
Distribution pattern of the FDG tracer in patients with neurodegenerative diseases and identify the regions of altered brain function specific for each clinical condition.

Locations

Country Name City State
n/a

Sponsors (1)

Lead Sponsor Collaborator
IRCCS San Raffaele

Outcome

Type Measure Description Time frame Safety issue
Primary FDG PET to measure brain areas of hypo or hyper regional metabolism in patients with neurodegenerative disease. Characterization of the different pathologies examined starting from the study of regional metabolism in individual subjects up to the study of the functional activity of the different brain circuits. 4 years
See also
  Status Clinical Trial Phase
Completed NCT05538455 - Investigating ProCare4Life Impact on Quality of Life of Elderly Subjects With Neurodegenerative Diseases N/A
Completed NCT05788133 - The Role of Humanoid Robot in Neuropsychological Assessment and Cognitive Training. N/A
Completed NCT05080777 - Pilot Pragmatic Clinical Trial to Embed Tele-Savvy Into Health Care Systems N/A
Completed NCT03295786 - Clinical Study to Test the Safety of CDNF by Brain Infusion in Patients With Parkinson's Disease Phase 1/Phase 2
Recruiting NCT04265482 - Community-based Cohort of Functional Decline in Subjective Cognitive Complaint Elderly
Not yet recruiting NCT02222779 - Quantification of Transition Metals N/A
Recruiting NCT01291550 - Electronic Nose for Diagnosis of Neurodegenerative Diseases Via Breath Samples N/A
Completed NCT01450891 - Health Technology Assessment of Diagnostic Approaches in Alzheimer's Disease N/A
Completed NCT01953523 - Safety and Clinical Outcomes Study: SVF Deployment for Orthopedic, Neurologic, Urologic, and Cardio-pulmonary Conditions N/A
Recruiting NCT06148233 - CSF1R PET Probe [18F]CSF-23 in Alzheimer's Disease Brain Imaging N/A
Completed NCT03538522 - A Double-Blind, Placebo-Controlled Safety and Efficacy Study of NA-831 Phase 2
Completed NCT06251830 - Increasing Diagnosis Rates While Reducing Examination Time: Can MR Fingerprinting Deliver on Its Promise?
Recruiting NCT04472130 - Neurodegenerative Diseases Registry
Completed NCT03353207 - Striatal Dopamine Transmission in Individuals With Isolated Rapid Eye Movement Sleep With Atonia: a Search for Precursor Biomarker for Neurodegeneration
Completed NCT05095870 - Evaluation of the Peripheral Nerve Ultrasound as a Diagnostic Tool in CANVAS Neuropathies
Recruiting NCT05784090 - Correlation Between Melatonin Levels in Different Biological Fluids
Completed NCT02108769 - Yogic Breathing Changes Salivary Components N/A
Recruiting NCT05508789 - A Study of Donanemab (LY3002813) in Participants With Early Symptomatic Alzheimer's Disease (TRAILBLAZER-ALZ 5) Phase 3
Recruiting NCT04820881 - Cerebrovascular Reactivity and Oxygen Metabolism as Markers of Neurodegeneration After Traumatic Brain Injury
Recruiting NCT05235802 - Long-term Follow-up in Severe Traumatic Brain Injury